-- Mylan Pharmaceuticals CEO Heather Bresch is expected to defend her company’s increase in EpiPen pricing when she testifies before Congress tomorrow by maintaining that the company ...

If the merger of Pfizer's off-patent drug unit and Mylan is approved, Mylan CEO Heather Bresch could earn more than $37.6 million in severance and vested benefits, according to The Pittsburgh Post ...

Under heated questioning from a Congressional committee, CEO Heather Bresch remained evasive about the drug's high prices. The committee members said they expect more answers in 10 days.